All News
Filter News
Found 532 articles
-
Positive Phase 3 Trial of DUPIXENT® (dupilumab) in Adolescents with Inadequately Controlled Moderate-to-severe Atopic Dermatitis
5/16/2018
U.S. regulatory submission for patients ages 12-17 planned for third quarter 2018
-
Regeneron Reports First Quarter 2018 Financial and Operating Results
5/3/2018
Regeneron Pharmaceuticals, Inc. announced financial results for the first quarter of 2018 and provided a business update.
-
Regeneron and its longtime development partner Sanofi are keeping their proverbial fingers crossed that their profitable collaboration will yield yet another approved treatment this year.
-
Sanofi: First-quarter 2018 Business EPS up 1.4% at CER
4/27/2018
Sanofi: First-quarter 2018 Business EPS up 1.4% at CER
-
EMA to Review DUPIXENT® (dupilumab) as Potential Treatment for Inadequately Controlled Moderate-to-Severe Asthma
4/3/2018
Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the European Medicines Agency (EMA) has accepted for review an application for DUPIXENT® (dupilumab) as an add-on maintenance treatment in certain adults and adolescents (12 years of age and older) with inadequately controlled moderate-to-severe asthma.
-
Realm Therapeutics announced today that its PR013, failed to show efficacy in its Phase II trial for allergic conjunctivitis.
-
Asthma patients may soon have a new treatment option.
-
FDA to Review DUPIXENT® (dupilumab) as Potential Treatment for Moderate-to-Severe Asthma
3/2/2018
Regeneron Pharmaceuticals, Inc. and Sanofi announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) of DUPIXENT® (dupilumab) as an add-on maintenance treatment in certain adults and adolescents (12 years of age and older) with moderate-to-severe asthma.
-
The stock market has been rocky recently, but overall the biotech market appears to have been comparatively stable.
-
The company eleased the pipeline update at its Q4 earnings report.
-
Regeneron Reports Fourth Quarter and Full Year 2017 Financial and Operating Results
2/8/2018
Regeneron today announced financial results for the fourth quarter and full year 2017 and provided a business update.
-
Sanofi Delivers 2017 Business EPS in Line With Guidance
2/7/2018
Fourth-quarter and 2017 accounts reflect the acquisition of the former Boehringer Ingelheim CHC business and the disposal of the Animal Health business.
-
Sanofi Delivers 2017 Business EPS(1) in Line With Guidance
2/7/2018
Fourth-quarter and 2017 accounts reflect the acquisition of the former Boehringer Ingelheim Consumer Healthcare (CHC) business.
-
Sanofi to Eliminate 400 U.S. Jobs
1/22/2018
Sanofi has announced major restructuring, which will involve layoffs. -
Regeneron Announces Approval of DUPIXENT (dupilumab) in Japan for the Treatment of Atopic Dermatitis
1/22/2018
Regeneron today announced that the MHLW in Japan has granted marketing and manufacturing authorization for DUPIXENT for the treatment of atopic dermatitis in adults not adequately controlled with existing therapies.
-
Regeneron Keeps Science at the Center
1/17/2018
Thirty years ago, neurologist Leonard S. Schliefer, MD, PhD, founded Regeneron, a life sciences company dedicated to discovering, developing and bringing new medications to the patients who need them. -
This build out of the executive team follows the closing of a $30 million Series B financing announced last year.
-
The two companies struck the deal in 2015.
-
The positive results are spurring the companies to begin seeking approval for the checkpoint inhibitor.
-
Sanofi Presents R&D Strategy and Innovative Pipeline
12/13/2017
The company will highlight the progress it has made against "Sustaining Innovation", a key pillar of its 2020 strategic roadmap, and advancing a differentiated portfolio addressing unmet needs.